Alumis Inc. (ALMS) Stock Price & Analysis
Alumis Inc. (ALMS) rose 5.37% to USD 20.01 as of June 10, 2026 at 01:59 UTC, according to Nexqual real-time market data.
ALMS last closed at USD 18.99; the session ranged USD 18.36–20.05 on volume of 1,363,384 shares. Market capitalization is $2.55B, with a 52-week range of USD 2.76–30.6 (NMS). Source: Nexqual, June 10, 2026 at 01:59 UTC.
Key Statistics (as of June 10, 2026 at 01:59 UTC)
| Price | USD 20.01 |
|---|---|
| Change | ▲ 5.37% (up) |
| Previous Close | USD 18.99 |
| Open | USD 19.32 |
| Day Range | USD 18.36 – 20.05 |
| 52-Week Range | USD 2.76 – 30.6 |
| Volume | 1,363,384 shares |
| Market Cap | $2.55B |
| Exchange | NMS |
Technical Analysis (ALMS)
Nexqual's technical model rates ALMS "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 01:59 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.02 (neutral) |
| vs SMA50 | Below (USD 22.94) |
| MACD | -1.15 (negative) |
Analyst Ratings (ALMS)
Wall Street analysts rate ALMS "None" based on 10 analysts, with a mean price target of USD 40.1 (range USD 25–55), per Nexqual as of June 10, 2026 at 01:59 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 40.1 |
| High Target | USD 55 |
| Low Target | USD 25 |
| Buy / Hold / Sell | 10 / 1 / 0 |
Earnings (ALMS)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.71 |
| Revenue Estimate | $3.62M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.74 vs est -0.83 ▲ beat |
| 2025-12-31 | USD -0.25 vs est -0.98 ▲ beat |
| 2025-09-30 | USD -1.06 vs est -1 ▼ miss |
| 2025-06-30 | USD -1.47 vs est -1.39 ▼ miss |
Source: Nexqual, June 10, 2026 at 01:59 UTC.
Financials & Fundamentals (ALMS)
| Total Revenue | $8.40M |
|---|---|
| Revenue Growth (YoY) | -90.00% |
| Gross Margin | +100.00% |
| Operating Margin | -5652.44% |
| Profit Margin | +0.00% |
| ROE | -64.57% |
| Debt / Equity | 6.29 |
| Current Ratio | 7.51 |
| Total Cash | $522.94M |
| Total Debt | $35.66M |
| Free Cash Flow | $-206.75M |
Source: Nexqual, June 10, 2026 at 01:59 UTC.
Financial Health Score (ALMS)
Nexqual rates Alumis Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 01:59 UTC.
| Growth | Critical — Revenue -90% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $523M cash vs $36M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$207M, burning cash |
| Efficiency | Critical — ROE -65%, ROA -58.8% |
Ownership (ALMS)
| Insider Ownership | +0.64% |
|---|---|
| Institutional Ownership | +99.78% |
| Shares Outstanding | 123.43M |
| Float | 85.87M |
| Short % of Float | +15.45% |
Source: Nexqual, June 10, 2026 at 01:59 UTC.
Leadership (ALMS)
Alumis Inc. is led by Martin Babler (age 60), President, CEO & Chairman, per Nexqual as of June 10, 2026 at 01:59 UTC.
| President, CEO & Chairman | Martin Babler (age 60) |
|---|---|
| Chief Scientific Officer | David M. Goldstein (age 59) |
| Chief Financial Officer | John R. Schroer C.F.A. (age 60) |
Major Backers & Investors (ALMS)
Notable institutional backers of Alumis Inc. include Foresite Capital Management V, LLC, Deep Track Capital, Lp, Samsara BioCapital, LLC, according to Nexqual as of June 10, 2026 at 01:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Foresite Capital Management V, LLC | 8.22% |
| Deep Track Capital, Lp | 5.49% |
| Samsara BioCapital, LLC | 5.14% |
| venBio Partners LLC | 3.67% |
| Cormorant Asset Management, LP | 3.2% |
| Nextech Invest, Ltd. | 2.87% |
| Price (T.Rowe) Associates Inc | 2.66% |
| T. Rowe Price | 1.5% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.01% |
| Vanguard Group | 6.45% |
Source: Nexqual, June 10, 2026 at 01:59 UTC.
From Alumis Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
- The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
- It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MBX | MBX Biosciences, Inc. | USD 29.87 | ▼ 1.35% |
| ARTV | Artiva Biotherapeutics, Inc. | USD 7.27 | ▲ 6.13% |
| MLYS | Mineralys Therapeutics, Inc. | USD 24.18 | ▲ 2.07% |
| ABVX | Abivax SA | USD 102.72 | ▲ 1.17% |
| CGON | CG Oncology, Inc. | USD 56.67 | ▲ 5.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:59 UTC. This page is informational and not investment advice.